Skip to main content
Premium Trial:

Request an Annual Quote

Qiagen Snips Ribbon on New US Headquarters

NEW YORK, Jan. 11 - Qiagen Sciences has opened its new manufacturing complex in biotech-rich Germantown, Md., the company announced on Friday.

 

The 200,000-square-foot facility, which becomes Qiagen's new North American headquarters for manufacturing, production, and research and development, will employ 100 R&D personnel and more than 200 manufacturing staff to develop and process DNA separation and purification products.

 

Manufacturing activities will start by the end of February, the company said. Qiagen is based in Venlo, the Netherlands.

 

Qiagen generates approximately 60 percent of its consolidated revenues in the United States, said Peer M. Schatz, CFO for Qiagen. The new facility "should have a positive impact on the company's exposure to currency fluctuations, as well as enhance logistics," he added.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.